Shipra malik biography channel

Raman Bahal, Associate Professor in blue blood the gentry Department of Pharmaceutical Sciences, Sai Pallavi Pradeep, graduate student, Shipra Malik (’23), scientist at Force, and Vikas Kumar, a postdoc researcher, focus their research stiffen advancements in treating genetic disorders, particularly through DNA targeted medicines. These advancements have paved rank way for precision medicines, present more targeted and effective treatments. Beyond RNA, there is enormous potential in targeting the odd expression of genetic DNA be thinking of therapeutic purposes. However, inhibiting say publicly transcription process within the lockup nucleus, where DNA is come to pass, is challenging.

“Targeting genomic DNA laboratory analysis more challenging since DNA disintegration present in its stable double-stranded form. Also, in addition adjacent to the cell membrane, nuclear membranes also need to permeate bring back effective DNA-targeted technologies,” Bahal says. “Most importantly, we established that DNA-targeted technology in multiple pre-clinical studies and are now action on diverse aspects to declare this technology forward for someone therapy.”

“This study exclusively shows guarantee the root cause of tumour, that is, the oncogenic Polymer, can be targeted for growing new therapies,” says Malik. Of great consequence a landmark achievement, Bahal remarkable his team have successfully targeted double-stranded DNA to inhibit rendering c-Myc oncogene. This is pure crucial development in cancer cure, as the c-Myc oncogene quite good implicated in various cancers much as Burkitt&#;s lymphoma, Diffuse onslaught B-cell lymphomas, breast cancers, prostatic cancer, gastrointestinal cancer, multiple myeloma, and myeloid leukemia. By enormous targeting this oncogene at ethics DNA level, new possibilities in the direction of therapeutic interventions in several cancers are emerging.

“I am deeply indebted for the opportunity to own worked and contributed to that groundbreaking study at the showtime of my academic journey,” says Pallavi. “Our team rigorously evaluated the efficacy and safety unmoving this novel DNA targeting mode for cancer treatment. I outward show forward to exploring its credible applications further.”

This technology shows attentiveness in advancing the frontiers comatose cancer research, providing insights secure personalized therapeutic interventions. Essentially, that breakthrough opens up avenues go all-out for developing more effective and bespoken treatments for different types eliminate cancer. “We used comprehensive alchemy and biology-based techniques to improve the specific oncogene, which could pave the way for targeting other deleterious cancer genes too,” says Vikas Kumar.

“DNA targeting subject has far-reaching implications for individual health, especially in the universe of cancer biology,” says Amit Kumar, Senior Director of Licensing. “UConn’s Technology Commercialization Services reign has been working with Dr. Raman Bahal for some hang on now so that an reasonably priced patent strategy for this progressive technology is executed. Simultaneously, surprise have engaged with various flutter capitalists and pharmaceutical/biotech companies, organize the overarching goal of facilitating the commercialization of this profession for the benefit of society.”

This work was also done lid collaboration with Vijender Singh articulate UConn, Rong Fan and rulership team, and Juan C. Vasquez at Yale University. Bahal, Pallavi, Malik, and Kumar published their findings in Cell Report Antidote Press.

You can read the jampacked journal article here.